Current status and perspectives in immunotherapy for metastatic melanoma.

about

Current status and perspectives in immunotherapy for metastatic melanoma.

Item

http://www.wikidata.org/entity/Q54574397

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Current status and perspectives in immunotherapy for metastatic melanoma.

@en

Current status and perspectives in immunotherapy for metastatic melanoma.

@nl

type

Item

label

Current status and perspectives in immunotherapy for metastatic melanoma.

@en

Current status and perspectives in immunotherapy for metastatic melanoma.

@nl

prefLabel

Current status and perspectives in immunotherapy for metastatic melanoma.

@en

Current status and perspectives in immunotherapy for metastatic melanoma.

@nl

P1476

Current status and perspectives in immunotherapy for metastatic melanoma

@en

P2093

Carolina Cimminiello

http://www.w3.org/2001/XMLSchema#string

Elena Marra

http://www.w3.org/2001/XMLSchema#string

Enrica Tanda

http://www.w3.org/2001/XMLSchema#string

Francesco De Rosa

http://www.w3.org/2001/XMLSchema#string

Italian Melanoma Intergroup (IMI)

http://www.w3.org/2001/XMLSchema#string

Laura Orgiano

http://www.w3.org/2001/XMLSchema#string

Laura Spano

http://www.w3.org/2001/XMLSchema#string

Lorenza Di Guardo

http://www.w3.org/2001/XMLSchema#string

Paola Queirolo

http://www.w3.org/2001/XMLSchema#string

Riccardo Marconcini

http://www.w3.org/2001/XMLSchema#string

P2860

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

P304

12452-12470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23746

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alfredo Falcone

Francesco Spagnolo

Luigia Stefania Stucci

Stefano Cavalieri

P577

2018-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29552325

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5844761

http://www.w3.org/2001/XMLSchema#string